Key result
Oral enlicitide reduces LDL-C by ~57 percentage points vs. placebo and improves goal attainment.
Why the study?
Many patients do not reach LDL-C goals with statins, and the use of injectable PCSK9 inhibitors is limited by their route of administration and cost, motivating evaluation of the oral PCSK9 inhibitor enlicitide.
Does oral enlicitide reduce LDL-C and improve lipid parameters safely compared with placebo in adults with dyslipidemia?
Meta-Analysis (n=3,588)
Double-blind
Does oral enlicitide reduce LDL-C and improve lipid parameters safely compared with placebo in adults with dyslipidemia?
Oral enlicitide achieves LDL-C reductions comparable to injectable PCSK9 monoclonal antibodies with a placebo-like short-term safety profile, offering a potential oral alternative for dyslipidemia management pending cardiovascular outcomes data.
Answers are grounded in this paper and cite their sources.
Enlicitide offers an oral PCSK9 inhibitor option with placebo-like short-term safety; extends lipid-lowering strategies for dyslipidemia beyond injectables.
Many patients do not reach low-density lipoprotein cholesterol (LDL-C) goals with statins, and the use of injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors is limited by the route of administration and cost. Enlicitide (MK-0616) is an oral macrocyclic peptide that inhibits PCSK9. We searched PubMed, Scopus, Web of Science, and the Cochrane Library through September 24, 2026, for randomized controlled trials comparing enlicitide with placebo in adults with dyslipidemia, pooled data with random-effects models, and performed dose–response meta-regression and Grading of Recommendations, Assessment, Development and Evaluations assessment. Three double-blind trials (3588 participants) were included. Enlicitide reduced LDL-C by 56.81 percentage points relative to placebo [95% confidence interval (CI), −62.19 to −51.44; high certainty] and increased attainment of LDL-C goals [risk ratio (RR), 27.82; 95% CI, 7.22–107.19]. It also reduced nonhigh-density lipoprotein cholesterol (−51.96 percentage points), apolipoprotein B (−47.53), and lipoprotein(a) (−24.86), whereas high-density lipoprotein cholesterol did not change significantly. Higher doses were associated with greater LDL-C reductions. Any adverse events (RR, 1.03; 95% CI, 0.98–1.09), serious adverse events (0.84; 0.68–1.04), discontinuations due to adverse events (0.76; 0.52–1.11), and deaths (0.95; 0.41–2.21) did not differ from placebo. Oral enlicitide produces LDL-C lowering of a magnitude similar to that of injectable PCSK9 antibodies, with a short-term safety profile comparable to placebo; its effect on cardiovascular events remains to be established.
No takes yet. Share an insight, caveat, or question.
Talkhan et al. (2026) conducted a meta-analysis in Dyslipidemia (n=3,588). Enlicitide (MK-0616) vs. Placebo was evaluated on Percentage point change in low-density lipoprotein cholesterol (LDL-C) relative to placebo (MD -56.81 percentage points, 95% CI -62.19 to -51.44). Oral enlicitide reduced LDL-C by 56.81 percentage points relative to placebo and increased LDL-C goal attainment.
Synapse has enriched 10 related papers. Consider them for comparative context: